WC
BIOTU

Wealthspring Capital’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Wealthspring Capital’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,935
Closed -$461K – 450
2021
Q4 		$461K Sell
45,935
-7,201
-14% -$72.9K 0.1% 275
2021
Q3 		$534K Sell
53,136
-7,400
-12% -$74.2K 0.13% 213
2021
Q2 		$611K Sell
60,536
-1,514
-2% -$15.2K 0.15% 186
2021
Q1 		$614K Buy
+62,050
New +$638K 0.17% 156

Other funds holding BIOTU

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wealthspring Capital's BIOTU Position: Q1 2022 in Review

Wealthspring Capital sold out of Biotech Acquisition Company Unit (BIOTU) in Q1 2022, closing a stake of 45,935 shares — an estimated $461K sold.

Wealthspring Capital first reported a position in BIOTU in Q1 2021 and held it in 4 quarters. The position peaked at $614K in Q1 2021. 10 funds tracked by Wall St. Rank hold BIOTU as of Q1 2022.

  • Wealthspring Capital reported no remaining Biotech Acquisition Company Unit position as of Q1 2022 after selling out during the quarter.
  • Wealthspring Capital sold 45,935 Biotech Acquisition Company Unit shares in Q1 2022, an estimated $461K.
  • Wealthspring Capital first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 4 quarters.
  • Wealthspring Capital's Biotech Acquisition Company Unit position peaked at $614K in Q1 2021.
  • 10 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q1 2022.

Based on Wealthspring Capital's 13F filing for Q1 2022, filed 10 May 2022.